| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/BBRC.2001.4816 |
| P8608 | Fatcat ID | release_cihkkug2bvfdrbt2nx2lslcdnm |
| P698 | PubMed publication ID | 11327712 |
| P2093 | author name string | Herbert JM | |
| Labouret C | |||
| Savi P | |||
| Guette F | |||
| Lupker J | |||
| Delesque N | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clopidogrel | Q410237 |
| P304 | page(s) | 379-383 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | P2y(12), a new platelet ADP receptor, target of clopidogrel | |
| P478 | volume | 283 |
| Q44044494 | A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation. |
| Q33811654 | Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease |
| Q37953465 | Antiplatelet options for secondary prevention in acute coronary syndromes |
| Q43746576 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure |
| Q24618777 | Central role of the P2Y12 receptor in platelet activation |
| Q40722550 | Cerebellar astrocytes co-express several ADP receptors. Presence of functional P2Y(13)-like receptors. |
| Q28578957 | Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells |
| Q36140286 | Circulating primers enhance platelet function and induce resistance to antiplatelet therapy. |
| Q28176560 | Clopidogrel for the secondary prevention of stroke |
| Q28199817 | Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention |
| Q28192676 | Clopidogrel-induced qualitative changes in thrombus formation correlate with stent patency in injured pig cervical arteries |
| Q28220732 | Clopidogrel: a review of its use in the prevention of thrombosis |
| Q40393685 | Clopidogrel: cardiologists' panacea or neurologists' headache? |
| Q35605112 | Clopidogrel: interactions with the P2Y12 receptor and clinical relevance |
| Q36407222 | Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma? |
| Q53005242 | Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. |
| Q95424391 | Comparative pharmacokinetics/pharmacodynamics of clopidogrel besylate and clopidogrel bisulfate in healthy Korean subjects |
| Q89604978 | Cross-Talk in Nucleotide Signaling in Glioma C6 Cells |
| Q34910745 | Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study |
| Q47709567 | Developments in the synthesis of the antiplatelet and antithrombotic drug (S)-clopidogrel. |
| Q35046114 | Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells |
| Q47889142 | Dynamical modelling of prostaglandin signalling in platelets reveals individual receptor contributions and feedback properties |
| Q46666595 | Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects |
| Q44316598 | Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP. |
| Q44120735 | Effects of a P2Y(12) receptor antagonist on the response of equine platelets to ADP. Comparison with human platelets |
| Q28165710 | Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial |
| Q37670190 | Emerging drugs for acute myocardial infarction |
| Q28195677 | Evidence with Antiplatelet Therapy and ADP-Receptor Antagonists |
| Q36023598 | Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence |
| Q40159944 | Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells. |
| Q44724822 | Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor |
| Q28192799 | Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses |
| Q46334176 | Haemolysis induced by α-toxin from Staphylococcus aureus requires P2X receptor activation. |
| Q34455950 | Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12. |
| Q43262474 | Identification of the active metabolite of ticlopidine from rat in vitro metabolites |
| Q34496403 | Identification, characterization, and inhibition of the platelet ADP receptors |
| Q50100776 | Impaired liver cytochrome P450 2C11 activity after dual antiplatelet therapy with aspirin and clopidogrel in rats |
| Q34568130 | Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel |
| Q44518755 | Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. |
| Q34141735 | Inhibition of platelet P2Y12 and alpha2A receptor signaling by cGMP-dependent protein kinase |
| Q24629255 | International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy |
| Q38403462 | Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study |
| Q63977060 | Invited Lectures : Overviews Purinergic signalling: past, present and future |
| Q24294523 | Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding |
| Q40573764 | N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression |
| Q28217935 | Normalization of platelet reactivity in clopidogrel-treated subjects |
| Q35044028 | Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179. |
| Q26861200 | P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells |
| Q34581514 | Pharmaceutical thrombosis prevention in cardiovascular disease |
| Q28221012 | Primary and secondary agonists can use P2X(1) receptors as a major pathway to increase intracellular Ca(2+) in the human platelet |
| Q35891375 | Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier |
| Q36936578 | Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension |
| Q46844321 | Reciprocal regulation of platelet responses to P2Y and thromboxane receptor activation |
| Q87245995 | Sequence-structure based phylogeny of GPCR Class A Rhodopsin receptors |
| Q53728226 | Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration. |
| Q38756994 | The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms. |
| Q28168596 | The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented |
| Q24675155 | The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts |
| Q46715801 | The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance |
| Q38151546 | The impact of germline mutations on targeted therapy |
| Q40161287 | Thrombin based gelatin matrix and fibrin sealant mediated clot formation in the presence of clopidogrel. |
| Q37943864 | Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke |
Search more.